- Home
- AKTX vs ACXP Comparison
AKTX vs ACXP Comparison
Compare AKTX & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- ACXP
- Stock Information
- Founded
- AKTX N/A
- ACXP 2017
- Country
- AKTX United States
- ACXP United States
- Employees
- AKTX N/A
- ACXP N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- ACXP Health Care
- Exchange
- AKTX Nasdaq
- ACXP Nasdaq
- Market Cap
- AKTX 41.8M
- ACXP 8.4M
- IPO Year
- AKTX N/A
- ACXP 2021
- Fundamental
- Price
- AKTX $1.17
- ACXP $0.49
- Analyst Decision
- AKTX
- ACXP Strong Buy
- Analyst Count
- AKTX 0
- ACXP 2
- Target Price
- AKTX N/A
- ACXP $10.00
- AVG Volume (30 Days)
- AKTX 27.5K
- ACXP 18.6M
- Earning Date
- AKTX 08-18-2025
- ACXP 08-08-2025
- Dividend Yield
- AKTX N/A
- ACXP N/A
- EPS Growth
- AKTX N/A
- ACXP N/A
- EPS
- AKTX N/A
- ACXP N/A
- Revenue
- AKTX N/A
- ACXP N/A
- Revenue This Year
- AKTX N/A
- ACXP N/A
- Revenue Next Year
- AKTX N/A
- ACXP N/A
- P/E Ratio
- AKTX N/A
- ACXP N/A
- Revenue Growth
- AKTX N/A
- ACXP N/A
- 52 Week Low
- AKTX $0.85
- ACXP $0.30
- 52 Week High
- AKTX $4.40
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- AKTX 45.49
- ACXP 51.01
- Support Level
- AKTX $1.10
- ACXP $0.46
- Resistance Level
- AKTX $1.18
- ACXP $0.56
- Average True Range (ATR)
- AKTX 0.07
- ACXP 0.10
- MACD
- AKTX 0.00
- ACXP -0.01
- Stochastic Oscillator
- AKTX 53.25
- ACXP 24.27
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.